Front Matter
Preliminary Material
PART I. Anticoagulation Medication Management
1. Introduction to Anticoagulation Management
2. Warfarin
3. Unfractionated Heparin
4. Low Molecular Weight Heparin and Fondaparinux
5. Parenteral Direct Thrombin Inhibitors
6. Thrombolytic Considerations When Used with Anticoagulants
7. Direct Oral Anticoagulants
8. Anticoagulation Reversal: Part I—Pharmacology of Agents Used for Reversal
9. Anticoagulation Reversal: Part II—Clinical Application
10. Transitions in Care—Periprocedural Bridging and Transitions Between Agents
PART II. Conditions Requiring Anticoagulation Therapy
12. Venous Thromboembolism Prevention
13. Venous Thromboembolism Treatment
14. Atrial Fibrillation
15. Acute Coronary Syndromes
16. Prosthetic Heart Valves
17. Mechanical Circulatory Support Devices
18. Heparin-Induced Thrombocytopenia
19. Pregnancy
20. Pediatrics
PART III. Practical Measuring, Monitoring, and Coagulation Laboratory Insights
21. Coagulation Laboratory Considerations
22. Thrombophilias
PART IV. Essentials for Practice Success
23. Models and Standards of Anticoagulation Care Delivery
24. Regulatory and Practice Resources
Back Matter
Appendix A. Coagulation Cascade
Appendix B. Agents Implicated in Drug-Induced Thromboembolic Diseases
Appendix C. Nutrition Influence on Anticoagulation
Appendix D. Anticoagulants in Management of Ischemic Stroke or Transient Ischemic Attacks
Appendix E. Citrate Anticoagulation
Appendix F. Examples of Available Bleeding Definitions
Appendix G. Types of CNS Hemorrhage
Appendix H. Disseminated Intravascular Coagulation
Appendix I. Nondrug Causes of Thrombocytopenia
Appendix J. Drug-Related Causes of Thrombocytopenia
Appendix K. Examples of Transfusion-Related Reactions
Appendix L. Considerations for Transitioning from aPTT to Anti-Xa to Manage Heparin Therapy
Appendix M. PIONEER AF-PCI
Appendix N. Betrixaban APEX Trial
Index

11. Considerations in Special Populations

in Anticoagulation Therapy
DOI:
https://doi.org/10.37573/9781585284900.011
Restricted access